High Profile Cannabis partners with Canna Pharma

High Profile Holdings Cannabis Corp.Cannabis Corp., a wholly owned subsidiary of New Leaf Ventures Inc., NLVVF NLV has executed a genetics transfer and buyback agreement with CannaPharmaRX Inc. CPMD.

High Profile strains are proven to produce 15 - 30% THC and 3.5% terpenes consistently, according to the company. This agreement will allow the transfer of genetics from High Profile's library for cultivation in Canna's facility in Cremona, Alberta. High Profile will have the ability to buy back material that meets certain standards or for a royalty, allowing Canna to sell both domestically and internationally.

Canna has the use-rights of the former Aurora Cannabis's ACB 55,000 square foot GMP capable facility. Canna took over operations over a year ago with the goal of restoring the facility back to its pharmaceutical grade standards. The experts at Canna have signed on to bring this goal to fruition.

This partnership will allow for selected strains to be brought to market through the High Profile retail brand while other strains will be grown by the cultivator and sold to their existing domestic and foreign customers. Any finished products containing High Profile strains sold by Canna will require a royalty payment back to High Profile on a monthly basis. The agreement establishes a wholesale price for products that meet the high standards that High Profile customers have come to expect from this agreement.

This is the place where money is raised, M&A starts, and companies meet key partners. On April 11 - 12 at the Fontainebleau Miami Beach Hotel in Florida.